News & Events

Disc Medicine to Present at the Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass. (May 21, 2021) – Disc Medicine, a company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc Medicine, will provide a corporate presentation on Thursday, June 3, 2021 at 2:00 p.m. ET at the Jefferies Virtual Healthcare Conference.

About Disc Medicine

Disc Medicine is a biopharmaceutical company dedicated to transforming the lives of patients with hematologic disorders. We are building a unique portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology. We are committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic diseases. For more information, please visit www.discmedicine.com.

Media Contacts:

Sarah Ellinwood
sellinwood@vergescientific.com
202.930.4762

More News

Disc Medicine Expands Hematology P...

Clinical-Stage Program is Positioned to Enter Phase 2 Study in Erythropoietic Protoporphyria (EPP) CAMBRIDGE, Mass. (May 27, 2021) – Disc Medicine, Inc. announced...


read more

Disc Medicine to Present at the Eu...

CAMBRIDGE, Mass. (May 24, 2021) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...


read more

Disc Medicine Appoints William Whi...

CAMBRIDGE, Mass. (January 13th, 2021) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...


read more

Disc Medicine to Present at the Vi...

CAMBRIDGE, Mass. (December 2, 2020) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...


read more

Disc Medicine to Present at the Pi...

CAMBRIDGE, Mass. (November 23, 2020) – Disc Medicine, a hematology company dedicated to the discovery and development of novel therapeutic candidates for...


read more

Disc Medicine Expands Scientific A...

Tomas Ganz, MD, PhD and Elizabeta Nemeth, PhD to Join Disc Medicine Scientific Advisory Board Cambridge, Mass. – October 13, 2020 –...


read more

Disc Medicine to Present at Citi&#...

Cambridge, Mass. – September 8, 2020 – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates...


read more

Disc Medicine Expands Leadership T...

Jonathan Yu Named Senior Vice President of Corporate Strategy William Savage, MD, PhD Appointed Vice President of Clinical Development Cambridge, Mass. –...


read more

John Quisel, JD, PhD Joins Disc Me...

Co-founder and Interim CEO Brian MacDonald to Serve as Senior Advisor and Director Cambridge, Mass. – January 28, 2020 – Disc Medicine,...


read more

Disc Medicine Completes $50 Millio...

Cambridge, Mass. – October 29, 2019 – Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that...


read more

Disc Medicine Expands Pipeline Foc...

Enters into exclusive agreement with AbbVie for series of Hemojuvelin Antagonist Monoclonal Antibodies Cambridge, Mass. – October 29, 2019 – Disc Medicine,...


read more

Introducing Disc Medicine, a New H...

Introducing Disc Medicine – we are a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell productions...


read more